Reported Earlier, Erasca Entered Into Exclusive License Agreements For Two Preclinical RAS Programs

5/17/24 1:19:50 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ERAS alert in real time by email

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors
Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success

Priced concurrent $160 million equity offering

Get the next $ERAS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ERAS

Date	Price Target	Rating	Analyst
11/18/2024	$6.00	Buy	Jefferies
3/11/2024	$8.00	Overweight	CapitalOne
1/5/2024	$11.00 → $6.00	Buy → Neutral	BofA Securities
10/11/2023	$10.00	Buy	H.C. Wainwright
3/30/2023	$9.00	Buy	Mizuho
2/24/2023	$10.00	Buy	Goldman
2/3/2023	$15.00	Equal-Weight → Overweight	Morgan Stanley
8/10/2021	$45.00	Outperform	Evercore ISI Group

More analyst ratings

$ERAS
Financials

Live finance-specific insights

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno
5/16/24 8:02:00 PM ET
$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care
Erasca Reports First Quarter 2024 Business Updates and Financial Results
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March
5/8/24 4:01:00 PM ET
$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care
Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results
Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 at 8:30 am ET SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and comm
3/27/24 4:01:00 PM ET
$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care

$ERAS
Market Insights

Live Market Insights

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With NRAS-Mutant Melanoma
Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors and has been dosed in over 500 patients to dateFavorable mOS and mPFS demonstrated in pooled analysis of Phase 1b and Phase 2 trials in NRASm melanomaRandomized Stage 1 readout for naporafenib plus trametinib vs. trametinib monotherapy expected in 2025SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the initiation of the global SEACRAFT-2 Phase 3 trial evaluating
6/18/24 8:05:36 AM ET
$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care
Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $4
Goldman Sachs analyst Chris Shibutani maintains Erasca (NASDAQ:ERAS) with a Buy and lowers the price target from $7 to $4.
5/28/24 11:40:09 AM ET
$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care
e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Thursday. Shares of e.l.f. Beauty, Inc. (NYSE:ELF) rose sharply during Thursday's session after the company reported better-than-expected fourth-quarter earnings. e.l.f. Beauty reported adjusted earnings of 53 cents per share, beating the 32-cent estimate, according to data from Benzinga Pro. Quarterly sales clocked in at $321.14 million, beating the $292.17 million analyst consensus estimate, primarily driven by strength across retailer and e-commerce channels. e.l.f. Beauty said it sees fiscal year earnings between $3.20 and $3.25 per share, versus the $3.51 per share estimate, and full-year revenue in a
5/23/24 10:26:28 AM ET
$ACIU
$AILE
$BCYC
$BORR
Biotechnology: Pharmaceutical Preparations
Health Care
Computer Software: Prepackaged Software
Technology

$ERAS
Press Releases

Fastest customizable press release news feed in the world

Erasca Reports Third Quarter 2024 Business Updates and Financial Results
Positive preliminary Phase 1b data in SEACRAFT-1 NRASm melanoma cohort bolsters conviction in ongoing SEACRAFT-2 registrational trial; Stage 1 randomized data expected in 2025 Strong execution across potentially best-in-class RAS targeting franchise; planned IND submissions on track Robust balance sheet with cash, cash equivalents, and marketable securities of $463 million as of September 30, 2024, is expected to fund operations into H1 2027 SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK path
11/12/24 4:01:00 PM ET
$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care
Erasca to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings. Guggenheim Securities Healthcare Innovation Conference (November 11 – 13, 2024)Location: InterContinental Hotel, Boston, MAFormat: Fireside Chat Date and Time: Tuesday, November 12, 2:00 pm Eastern Time Jefferies London Healthcare Conference (November 19 – 21, 2024)Location: The Waldorf Hilton, London, U
11/5/24 8:00:00 AM ET
$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
Positive preliminary Phase 1b SEACRAFT-1 data for naporafenib plus trametinib reinforce therapeutic potential in NRASm melanoma and further support ongoing Phase 3 SEACRAFT-2 trial SEACRAFT-2 has potential for approval based on alignment with US and European regulatory agencies on path for tissue-specific indication in melanoma; Stage 1 randomized data expected in 2025 Rapid progress across RAS targeting franchise; planned IND submissions remain on track Erasca to host investor event today at 8:30 AM Eastern Time SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commerc
10/24/24 8:00:00 AM ET
$ERAS
Biotechnology: Pharmaceutical Preparations
Health Care

Reported Earlier, Erasca Entered Into Exclusive License Agreements For Two Preclinical RAS Programs

Chat with this insight

Recent Analyst Ratings for $ERAS

$ERAS Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Erasca Inc.

Amendment: SEC Form SC 13G/A filed by Erasca Inc.

SEC Form SC 13G filed by Erasca Inc.

$ERAS Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Casdin Alexander W. bought $181,920 worth of shares (80,000 units at $2.27) (SEC Form 4)

Start Valerie Denise Harding bought $18,480 worth of shares (10,000 units at $1.85) (SEC Form 4)

Lim Jonathan E bought $1,696,179 worth of shares (1,000,000 units at $1.70) (SEC Form 4)

$ERAS Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Varney Michael David

SEC Form 4 filed by Director Start Valerie Denise Harding

SEC Form 4 filed by Director Liu Jean I

$ERAS Leadership Updates

Live Leadership Updates

$ERAS SEC Filings

Erasca Appoints Jean Liu to its Board of Directors

Erasca Strengthens Leadership Team with Two Key Executive Appointments

SEC Form 10-Q filed by Erasca Inc.

Erasca Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Erasca Inc. filed SEC Form 8-K: Other Events

$ERAS Financials

Live finance-specific insights

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Erasca Reports First Quarter 2024 Business Updates and Financial Results

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

$ERAS Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Jefferies initiated coverage on Erasca with a new price target

CapitalOne initiated coverage on Erasca with a new price target

Erasca downgraded by BofA Securities with a new price target

$ERAS Market Insights

Live Market Insights

Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib In Patients With NRAS-Mutant Melanoma

Goldman Sachs Maintains Buy on Erasca, Lowers Price Target to $4

e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday

$ERAS Press Releases

Fastest customizable press release news feed in the world

Erasca Reports Third Quarter 2024 Business Updates and Financial Results

Erasca to Present at Upcoming Investor Conferences

Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise

Recent Analyst Ratings for
$ERAS

$ERAS
Large Ownership Changes

$ERAS
Insider Purchases

$ERAS
Insider Trading

$ERAS
Leadership Updates

$ERAS
SEC Filings

$ERAS
Financials

$ERAS
Analyst Ratings

$ERAS
Market Insights

$ERAS
Press Releases